There are 2867 resources available
474P - Evaluation of gelatinase-responsive copolymeric nanoparticles targeting PD-1 and TGF-β pathways for treating immune-resistant tumor
Presenter: Yingtzu Yen
Session: Poster session 13
475P - Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
Presenter: Hans Gelderblom
Session: Poster session 13
476P - First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
Presenter: Fredericus Eskens
Session: Poster session 13
477P - MTL-STING increases STING expression and potentiates efficacy of checkpoint inhibitor in murine preclinical model
Presenter: Choon Ping Tan
Session: Poster session 13
479P - Synergistic anti-tumor effect of Allocetra-OTS in combination with immune checkpoint inhibitors (ICI)/chemotherapy/CAR T, through in-vivo reprogramming of macrophages
Presenter: Dror Mevorach
Session: Poster session 13
480P - CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)
Presenter: Philippe Cassier
Session: Poster session 13
481P - A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab
Presenter: Manish Sharma
Session: Poster session 13
482P - Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 13
483P - Pre-clinical and early clinical assessment of the safety and anti-tumor activity of RP12146, a PARP1/2 inhibitor in solid tumors
Presenter: Piotr Tomczak
Session: Poster session 13